← Back to Search
Emerging Drugs For Immune Thrombocytopenia (ITP)
Published 2017 · Medicine
Save to my Library
Download via 🐼 PaperPanda Download via oaDOI Download via OAB Download via LibKey Download via Google Google ScholarAnalyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
ABSTRACT Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody production against platelets, increased platelet destruction, and, in some cases, impaired thrombopoiesis. The majority of affected patients have significant bleeding risks due to low platelet counts and require treatment. The etiology of ITP is an immunological labyrinth. Currently available treatment options are usually not only nonspecific, but are also associated with some risks. Areas covered: Several useful drugs for the treatment of ITP are currently available. Furthermore, ongoing trials with new drugs and preclinical development of additional drugs may help to improve and determine their value. Expert opinion: ITP is a heterogeneous complex requiring individualized treatment. None of the available drugs are specific, nor are they invariably safe and effective. Thus, the need for specific therapy is evident.
This paper references
Deposition of the terminal C5b‐9 complement complex on erythrocytes by human red cell autoantibodies
A. Salama (1983)
R. McMillan (1983)
Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody.
S. Clarkson (1986)
Treatment of refractory immune thrombocytopenic purpura with an anti-Fcγ-receptor antibody
S. Clarkson (1986)
Use of Rh antibodies in the treatment of autoimmune thrombocytopenia.
A. Salama (1992)
Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature.
C. Schiavotto (1993)
Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients.
A. Scaradavou (1997)
Immune thrombocytopenic purpura in pregnancy.
G. Christiaens (1998)
Idiopathic thrombocytopenia purpura: Treatment patterns and an analysis of cost associated with intravenous immunoglobulin and anti-D therapy.
K. Simpson (1998)
A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura.
G. Newman (2001)
Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
J. Davis (2001)
Morbidity and mortality in adults with idiopathic thrombocytopenic purpura.
J. Portielje (2001)
A dose of 75 μg/kg/d of i.v. anti‐D increases the platelet count more rapidly and for a longer period of time than 50 μg/kg/d in adults with immune thrombocytopenic purpura
G. Newman (2001)
Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?
N. Cooper (2002)
Immune thrombocytopenic purpura.
I. Khouri (2002)
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
K. Kalunian (2002)
Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with antiCD154: a randomized, double-blind, placebo-controlled trial
KC Kalunian (2002)
Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti‐D with routine care
J. George (2003)
Targeting dendritic cells with CD44 monoclonal antibodies selectively inhibits the proliferation of naive CD4+ T‐helper cells by induction of FAS‐independent T‐cell apoptosis
C. Termeer (2003)
Idiopathic thrombocytopenic purpura: an old disease revisited in the era of evidence-based medicine.
F. Rodeghiero (2003)
In Vitro–expanded Antigen-specific Regulatory T Cells Suppress Autoimmune Diabetes
Q. Tang (2004)
Platelets: signaling cells in the immune continuum.
A. Weyrich (2004)
Efficacy and safety of anti‐D given by subcutaneous injection to patients with autoimmune thrombocytopenia
O. Meyer (2004)
Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura.
M. Kuwana (2004)
IGIV-C, a novel intravenous immunoglobulin: evaluation of safety, efficacy, mechanisms of action, and impact on quality of life.
J. Bussel (2004)
Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
M. Tarantino (2006)
Anti-interleukin-2 receptor antibody (daclizumab) treatment of corticosteroid-refractory autoimmune thrombocytopenic purpura.
P. Fogarty (2006)
Suppression of Disease in New Zealand Black/New Zealand White Lupus-Prone Mice by Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells1
K. Scalapino (2006)
Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Y. Kaneko (2006)
Prevalence of immune thrombocytopenia: analyses of administrative data
J. Segal (2006)
Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain.
T. Raju (2006)
A novel antigen‐specific capture assay for the detection of platelet antibodies and HPA‐1a phenotyping
O. Meyer (2006)
The epidemiology of immune thrombocytopenic purpura
P. Fogarty (2007)
High‐level serum B‐cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura
F. Emmerich (2007)
Modulation of immune response with cytotoxic T‐lymphocyte‐associated antigen 4 immunoglobulin‐induced anergic T cells in chronic idiopathic thrombocytopenic purpura 2
X. Zhang (2007)
Cytokines for the treatment of thrombocytopenia.
S. Ciurea (2007)
Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura
D. Arnold (2007)
Immune thrombocytopenic purpura in adults
B. Godeau (2007)
A cost‐utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)
Sarah H. O'Brien (2007)
Epidemiology and pathophysiology of immune thrombocytopenic purpura
T. Gernsheimer (2008)
Is splenectomy still the gold standard for the treatment of chronic ITP?
F. Rodeghiero (2008)
The effect of anti‐CD40 ligand in immune thrombocytopenic purpura
Vivek L. Patel (2008)
Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey
C. Snyder (2008)
Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura.
X. Zhang (2008)
Self‐reported health‐related quality of life in adults with chronic immune thrombocytopenic purpura
R. McMillan (2008)
Health-related quality of life of immune thrombocytopenic purpura patients: results from a webbased survey
CF Snyder (2008)
Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk.
A. Podolanczuk (2009)
Cost and mortality associated with hospitalizations in patients with immune thrombocytopenic purpura
M. Danese (2009)
Subcutaneous anti-d globulin application is a safe treatment option of immune thrombocytopenia in children
M. Trebo (2009)
Analysis of the impact and burden of illness of adult chronic ITP in the US
M. Saleh (2009)
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody.
D. Goldenberg (2009)
Investigation of whether the acute hemolysis associated with Rho(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model
Ann Reed Gaines (2009)
The ITP syndrome: pathogenic and clinical diversity.
D. Cines (2009)
Subcutaneous anti‐D treatment of idiopathic thrombocytopenic purpura in children
M. Kjaersgaard (2009)
Properties and structurefunction relationships of veltuzumab (hA20), a humanized antiCD20 monoclonal antibody
DM Goldenberg (2009)
CD20-targeted therapy: the next generation of antibodies.
T. van Meerten (2010)
Impact of ITP on physician visits and workplace productivity
M. Tarantino (2010)
Toxicities of the thrombopoietic growth factors.
A. Cuker (2010)
International consensus report on the investigation and management of primary immune thrombocytopenia.
D. Provan (2010)
Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
B. Cheson (2010)
Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic‐uremic syndromes
Deirdra R. Terrell (2010)
Costs of managing severe immune thrombocytopenia in adults: a retrospective analysis
M. Khellaf (2010)
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia.
F. Zaja (2010)
The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports
D. Terrell (2010)
Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg) (EMA/CHMP/BPWP/94033/2007 rev.2)
Immune thrombocytopenia. Hematology
A Cuker (2010)
A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
A. Cuker (2011)
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.
C. Neunert (2011)
Neonatal Fc Receptor Blockade by Fc Engineering Ameliorates Arthritis in a Murine Model
Dipesh A. Patel (2011)
Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma
Karen Fröhlich (2011)
Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review
Y. Kurata (2011)
Current treatment options for primary immune thrombocytopenia
A. Salama (2011)
Amelioration of murine immune thrombocytopenia by CD44 antibodies: a potential therapy for ITP?
A. Crow (2011)
Sequence of treatments for adults with primary immune thrombocytopenia
J. George (2012)
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia.
T. Robak (2012)
Autoantibody‐mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP)
A. Najaoui (2012)
Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
G. Blackhouse (2012)
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia.
Vivek L. Patel (2012)
The burden of immune thrombocytopenia in adults: Evaluation of the thrombopoietin receptor agonist romiplostim
R. Deuson (2012)
P. Basciano (2012)
Erratum to: Cost Effectiveness of Romiplostim for the Treatment of Chronic Immune Thrombocytopenia in Ireland
D. Lee (2013)
Individualized treatment for immune thrombocytopenia: predicting bleeding risk.
C. Neunert (2013)
Adoptive transfer of ex vivo expanded regulatory T cells in an autoimmune hepatitis murine model restores peripheral tolerance
P. Lapierre (2013)
Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia.
S. Gudbrandsdottir (2013)
Tolerogenic dendritic cells as a therapy for treating lupus.
C. Llanos (2013)
Bench-to-bedside review: Platelets and active immune functions - new clues for immunopathology?
O. Garraud (2013)
Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim, rituximab and vincristine.
K. Okazuka (2013)
Immune Thrombocytopenia (ITP)
B. Psaila (2013)
Rozrolimupab, a first-in-class recombinant monoclonal antibody product for primary immune thrombocytopaenia
S. Easdale (2013)
Bortezomib for the treatment of previously untreated multiple myeloma.
A. Romano (2013)
Dapsone for primary immune thrombocytopenia in adults and children: an evidence‐based review
C. Rodrigo (2013)
Low‐dose anti‐CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study
H. Liebman (2013)
Pathophysiology and management of primary immune thrombocytopenia
H. Kashiwagi (2013)
Platelets as cellular effectors of inflammation in vascular diseases.
M. Rondina (2013)
Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada
M. Pettigrew (2013)
Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus.
L. Quartuccio (2014)
Regulatory dendritic cell therapy: from rodents to clinical application.
D. Raïch-Regué (2014)
Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?
Ilse Van Brussel (2014)
Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up.
N. Marek-Trzonkowska (2014)
Comparison of the glycosylation of in vitro generated polyclonal human IgG and therapeutic immunoglobulins.
Ilja Ritamo (2014)
Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia: an adjusted comparison of mortality and morbidity
G. Moulis (2014)
Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France.
G. Moulis (2014)
The temporary use of thrombopoietin‐receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study
M. Mahévas (2014)
PRTX‐100 and methotrexate in patients with active rheumatoid arthritis: A Phase Ib randomized, double‐blind, placebo‐controlled, dose‐escalation study
Edward W. Bernton (2014)
Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin G
W. J. R. Fokkink (2015)
Sustained response after discontinuation of short-and medium-term treatment with eltrombopag in patients with immune thrombocytopenia
T. González-López (2015)
Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults
K. Kikuchi (2015)
Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.
D. Pinelli (2015)
[Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
M. F. López (2015)
Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis.
S. Chugh (2015)
Engineering antigen-specific immunological tolerance.
Stephan Kontos (2015)
Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus
N. Jordan (2015)
Clinically and/or Serologically Misleading Findings Surrounding Immune Haemolytic Anaemias
A. Salama (2015)
Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review
A. Salama (2015)
Management of immune thrombocytopenia in adults: a population‐based analysis of the French hospital discharge database from 2009 to 2012
M. Michel (2015)
Biotherapies targeting T and B cells: from immune suppression to immune tolerance.
L. Chatenoud (2015)
Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study
M. Urowitz (2015)
Human autoimmune diseases: a comprehensive update
Lifeng Wang (2015)
Feasibility of Romiplostim Discontinuation in Adult Thrombopoietin-Receptor Agonist Responsive Patients with Primary Immune Thrombocytopenia: An Observational Retrospective Report in Real Life Clinical Practice
M. Carpenedo (2015)
Coste por paciente con respuesta a romiplostim y rituximab en el tratamiento de la trombocitopenia inmune primaria en España
M. López (2015)
Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study.
G. Moulis (2015)
Role of Complement in Autoimmune Hemolytic Anemia
S. Berentsen (2015)
Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial
W. Ghanima (2015)
Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells.
Jessica S. Suwandi (2015)
Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®
Thi-Thanh Loan Nguyen (2015)
Novel insights into anti-CD40/CD154 immunotherapy in transplant
DF Pinelli (2015)
Thrombopoietin Receptor Agonists Are Often Ineffective in Immune Thrombocytopenia and/or Cause Adverse Reactions: Results from One Hand
F. Depré (2016)
Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.
Qianxia Zhang (2016)
A comprehensive review of the neonatal Fc receptor and its application in drug delivery.
J. P. Martins (2016)
CD44 Antibody Inhibition of Macrophage Phagocytosis Targets Fcγ Receptor– and Complement Receptor 3–Dependent Mechanisms
A. Amash (2016)
Is Autoimmune Thrombocytopenia Itself the Primary Disease in the Presence of Second Diseases Data from a Long-Term Observation
N. Aboud (2016)
Small molecule phagocytosis inhibitors for immune cytopenias.
A. Neschadim (2016)
Autoimmune regulator and self‐tolerance – molecular and clinical aspects
J. Abramson (2016)
Regulatory T cell therapy for type 1 diabetes: May the force be with you.
S. Gitelman (2016)
Platelets are versatile cells: New discoveries in hemostasis, thrombosis, immune responses, tumor metastasis and beyond
Xiaohong Xu (2016)
Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity.
Xiaojie Yu (2016)
Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia.
M. Mahévas (2016)
Controversies in the treatment of immune thrombocytopenia
A. Cuker (2016)
IVIG in autoimmune disease - Potential next generation biologics.
A. Zuercher (2016)
How I treat refractory immune thrombocytopenia.
A. Cuker (2016)
Combining antigen and immunomodulators: Emerging trends in antigen-specific immunotherapy for autoimmunity.
L. Northrup (2016)
Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells
M. König (2016)
Development of T‐cell tolerance utilizes both cell‐autonomous and cooperative presentation of self‐antigen
Justin S. A. Perry (2016)
New aspects on the efficacy of high‐dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia
B. Mayer (2017)
Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.
F. Depré (2018)
• New aspect in development of immune therapy
• Comprehensive review on the role of platelets in immune system
Efficacy and safety of drugs used in treatment of autoimmune thrombocytopenia
• Subcutaneous use of anti-D in ITP
This paper is referenced by
Immune thrombocytopenia: the patient’s perspective
C. Kruse (2021)
FcRn antagonists in ITP
A. Newland (2021)
Downregulation of microRNA-155-5p prevents immune thrombocytopenia by promoting macrophage M2 polarization via the SOCS1-dependent PD1/PDL1 pathway.
Yuying Chang (2020)
Inhibition of platelet phagocytosis as an in vitro predictor for therapeutic potential of RBC antibodies in murine ITP.
Ramsha Khan (2020)
Retrospective analysis of different regimens for Chinese adults with severe newly diagnosed immune thrombocytopenia
Xiaoyue Wang (2020)
Pharmaceutical immunoglobulins reduce neutrophil extracellular trap formation and ameliorate the development of MPO-ANCA-associated vasculitis
R. Uozumi (2019)
Treatment of primary and secondary immune thrombocytopenia
R. Kado (2019)
Fostamatinib for persistent/chronic adult immune thrombocytopenia.
A. Newland (2018)
Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia
F. Rodeghiero (2018)
Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice
F. Depré (2018)
Successful treatment of bleeding with tranexamic acid in a series of 12 patients with immune thrombocytopenia
B. Mayer (2017)